Business Context and Reporting Period
This Form 8-K Current Report was filed by D-Wave Quantum Inc. on June 10, 2025. The filing discloses the entry into a Material Definitive Agreement regarding an "at-the-market" equity offering program.
Key Financial Metrics and Liquidity
- Offering Capacity: The Company may sell up to $400 million in aggregate offering price of common stock under the new Sales Agreement.
- Liquidity Status: Management stated that the cash balance as of March 31, 2025, is sufficient to fund the Company to profitability.
- Compensation: Agents are entitled to compensation of up to 3.0% of the gross sales price of shares sold.
- Revenue/Profit/Cash Flow: The filing text does not provide specific values for revenue, net income, operating cash flow, or debt levels for the current period.
Material Changes
The primary material change is the execution of a Sales Agreement with multiple agents (including Needham & Company, Evercore Group, and TD Securities) to facilitate the sale of common stock. This agreement is pursuant to a registration statement on Form S-3 that became effective on June 10, 2025.
Guidance, Outlook, and Risks
- Use of Proceeds: Proceeds from any sales will be used for general corporate purposes, including capital expenditures, potential acquisitions, business expansion, and working capital.
- Management Outlook: Management believes existing cash reserves are sufficient to reach profitability without immediate reliance on the new offering.
- Flexibility: The Company is not obligated to sell any shares under the agreement. The offering can be terminated by the Company or Agents with five business days' notice or upon certain adverse events.
- Risks: The sale of shares may result in dilution to existing shareholders. The agreement includes indemnification provisions for the Agents against certain liabilities.
Investor Verification Checklist
- Verify the exact cash balance as of March 31, 2025, in the most recent quarterly report (10-Q) to assess the runway to profitability.
- Review the effective Form S-3 (File No. 333-287747) and the attached Prospectus Supplement for detailed risk factors.
- Monitor future filings for actual sales volumes and pricing under the Sales Agreement to gauge dilution impact.
- Confirm the Company's current debt obligations and interest coverage ratios in periodic reports, as this filing does not detail debt levels.